Previously, FCGR2B was believed to be expressed exclusively on B cells and innate immune cells, but recent studies have demonstrated a significant upregulation of FCGR2B on tumor-infiltrating effector CD8+ T cells, suggesting that it may serve as a novel T cell checkpoint in anti-tumor immunity [40]. This evidence concerns the gene CD8A and neoplasm.